Fate Therapeutics has named Brian Powl as chief commercial officer as it begins charting a launch pathway for its cell product franchises in hematologic malignancies and solid tumors.

Powl brings commercial leadership experience in those areas. He served as global commercial CAR-T lead at Celgene, a role in which he oversaw a global portfolio of new cell therapy products. He also led Celgene’s flagship multiple myeloma franchise, helming marketing for Revlimid and Pomalyst as well as the biotech’s global commercial operations group for oncology products outside the U.S.

He joins from MEI Pharma, where he was SVP, commercial development and marketing. Prior to his Celgene tenure, Powl held sales and marketing positions at Novartis Oncology and Centocor.